Wall Street futures may point lower but several stocks are heading skyward before the bell.
Nektar Therapeutics (NASDAQ:NKTR) added over 26% in pre-market deals to US$41 after the firm and medtech giant Bristol-Myers Squibb reported the first presentation of data from PIVOT-02 Phase 1/2 study showing potential benefits.
Elsewhere, Nova Lifestyle Inc (NASDAQ: NVFY) added over 64% to US$2.92 after it reported third quarter earnings of $0.11 per share on revenues of $33.22 million.
Meanwhile, T-Mobile US Inc (NASDAQ: TMUS) added over 5% on Monday to US$ $59.70 in pre-market trading after gaining 1.43% on Friday.
Protalix BioTherapeutics Inc (NYSE: PLX) added around 7% in pre-market to US$260 after the company revealed it had received a positive opinion for Orphan designation for PRX-102 from the Committee for Orphan Medicinal Products of the European Medicines Agency.